A Phase I Dose Escalation, Multi-center, Open-label Study of HSP990 Administered Orally Once Weekly in Adult Japanese and Korea Patients With Advanced Solid Malignancies.

Trial Profile

A Phase I Dose Escalation, Multi-center, Open-label Study of HSP990 Administered Orally Once Weekly in Adult Japanese and Korea Patients With Advanced Solid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Dec 2012

At a glance

  • Drugs HSP 990 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 23 Aug 2012 Status changed from active, no longer recruiting to completed.
    • 14 Mar 2012 Planned number of patients changed from 39 to 40 as reported by ClinicalTrials.gov.
    • 14 Mar 2012 Planned End Date changed from 1 Jul 2012 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top